ALK and non-small cell lung carcinoma: For example, according to data from the European Thoracic Oncology Platform Lungscape iBiobank, 5.4 % of patients with NSCLC are ALK-positive, among them 79.2 % were AC (Letovanec et al., 2018[49]).